Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Stifel Financial Corp purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 16,976 shares of the company’s stock, valued at approximately $327,000.

Several other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at about $27,000. Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals during the third quarter worth about $30,000. nVerses Capital LLC acquired a new position in shares of Syndax Pharmaceuticals in the second quarter worth approximately $33,000. Finally, Inspire Investing LLC boosted its holdings in Syndax Pharmaceuticals by 15.0% in the second quarter. Inspire Investing LLC now owns 17,290 shares of the company’s stock valued at $355,000 after acquiring an additional 2,258 shares during the last quarter.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock opened at $12.77 on Friday. The stock has a market capitalization of $1.09 billion, a PE ratio of -3.52 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a 52 week low of $12.52 and a 52 week high of $25.34. The stock has a 50 day moving average price of $16.62 and a two-hundred day moving average price of $19.02.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the previous year, the business posted ($0.73) EPS. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on SNDX shares. The Goldman Sachs Group raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. UBS Group began coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 price target for the company. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $36.90.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).